ITC to Acquire Sresta Natural Bioproducts for ₹472.50 Crore

On April 21, 2025, ITC share price dropped ~2% in the morning trade, reaching a day low of ₹421.40 at 10:15 AM, after opening at ₹429.85 on BSE. The fall in ITC share price came despite the announcement of a new acquisition by the diversified FMCG giant.

On April 17, 2025, ITC Ltd released an exchange filing after the market hours, wherein, it stated that it has signed share purchase agreements (SPA) for acquisition of a 100% stake in Sresta Natural Bioproducts Private Limited (SNBPL).

Objective and Impact of Acquisition

The acquisition of Sresta Natural Bioproducts Private Limited aligns with the company’s strategy to facilitate its future-ready portfolio.

The completion of the transaction will cement ITC’s presence and market standing in the high-growth organic products segment in both Indian and overseas markets. The domestic organic food products industry offers substantial growth opportunities backed by the increasing health and environmental consciousness, growing household incomes and new age distribution channels.

ITC will pay a consideration of up to ₹472.50 crores on a cash-free, debt-free basis. This comprises ₹400 crores payable upfront at Closing and up to ₹72.50 crores payable in the next 24 months post-closing.

About Sresta Natural Bioproducts Private Limited

SNBPL is a pioneer and leading player in the organic packaged staples category. The company has over the years, built a strong network of appx. 27,500 farmers and appx. 1.4 lakh acres of certified organic land across 71 clusters in 10 states. SNBPL has a wide range of products and enjoys strong brand equity and also a well-established presence in the US markets with its own distribution set-up.

Also Read: Check How Historically ITC Group Has Evolved 

Conclusion

The acquisition of Sresta Natural Bioproducts Private Limited by ITC presents significant growth opportunities for ITC in the high-growth organic products segment in both Indian and overseas markets.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.